NZ629256A - Vaccine compositions - Google Patents

Vaccine compositions

Info

Publication number
NZ629256A
NZ629256A NZ629256A NZ62925610A NZ629256A NZ 629256 A NZ629256 A NZ 629256A NZ 629256 A NZ629256 A NZ 629256A NZ 62925610 A NZ62925610 A NZ 62925610A NZ 629256 A NZ629256 A NZ 629256A
Authority
NZ
New Zealand
Prior art keywords
klh
saccharide
vaccine compositions
lys
peptide conjugate
Prior art date
Application number
NZ629256A
Other languages
English (en)
Inventor
Ferhana Zaman
Lavinia Marina Lewis
Brandi Rae Osborne
Sandipan Sinha
Jennifer Marie Thorn
Syed Saleem Ahmed
Iii John Joseph Buckley
Original Assignee
Celldex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celldex Therapeutics Inc filed Critical Celldex Therapeutics Inc
Publication of NZ629256A publication Critical patent/NZ629256A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ629256A 2009-12-22 2010-12-08 Vaccine compositions NZ629256A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28908309P 2009-12-22 2009-12-22
NZ600978A NZ600978A (en) 2009-12-22 2010-12-08 Vaccine compositions

Publications (1)

Publication Number Publication Date
NZ629256A true NZ629256A (en) 2016-02-26

Family

ID=43797591

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ629256A NZ629256A (en) 2009-12-22 2010-12-08 Vaccine compositions
NZ600978A NZ600978A (en) 2009-12-22 2010-12-08 Vaccine compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ600978A NZ600978A (en) 2009-12-22 2010-12-08 Vaccine compositions

Country Status (13)

Country Link
US (3) US20130034573A1 (https=)
EP (2) EP2515934B1 (https=)
JP (2) JP6007105B2 (https=)
KR (1) KR20120120185A (https=)
CN (2) CN102762224A (https=)
AU (1) AU2010334428B2 (https=)
CA (1) CA2785585A1 (https=)
IL (1) IL220308A0 (https=)
MX (1) MX337070B (https=)
NZ (2) NZ629256A (https=)
RU (1) RU2581020C2 (https=)
SG (2) SG181628A1 (https=)
WO (1) WO2011077309A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2536399T (pt) * 2010-02-21 2020-02-06 Bayer Healthcare Llc Método para ativação e conjugação de biomoléculas
KR101502360B1 (ko) * 2013-03-20 2015-03-25 주식회사 옵티팜 신규한 국내형 돼지생식기호흡기증후군 바이러스
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
KR20210027493A (ko) * 2018-07-19 2021-03-10 주식회사 헬릭스미스 네이키드 dna 유전자 요법을 위한 동결 건조된 약제학적 조성물
US20220273755A1 (en) * 2019-11-21 2022-09-01 Multiple Fortune Holding Limited Pharmaceutical composition, use and method for applying ganoderma microsporum immunomodulatory protein and keyhole limpet hemocyanin in carcinoma treatment

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH600453A5 (https=) 1976-12-30 1978-06-15 Autelca Ag
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
EP0491007B1 (en) * 1989-09-08 1996-03-13 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
WO1996016988A1 (en) * 1994-11-28 1996-06-06 Thomas Jefferson University Reagents and processes for targeting mutant epidermal growth factor receptors
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
EP1003850B1 (en) 1997-06-06 2009-05-27 The Regents of the University of California Inhibitors of dna immunostimulatory sequence activity
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
ES2214722T3 (es) * 1997-07-31 2004-09-16 Metra Biosystems, Inc. Metodo de ensayo de peptidos de colageno.
ATE421527T1 (de) * 1997-08-27 2009-02-15 Novartis Vaccines & Diagnostic Molekular-mimetika von meningokokkus b epitopen
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
TW570805B (en) * 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
KR100629028B1 (ko) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
ES2572834T3 (es) 1999-02-17 2016-06-02 Csl Limited Complejos inmunogénicos y métodos relacionados con los mismos
ATE459373T1 (de) 1999-03-19 2010-03-15 Glaxosmithkline Biolog Sa Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae
JP2001163801A (ja) * 1999-04-02 2001-06-19 Oriental Yeast Co Ltd 乾燥ｃ反応性タンパク質組成物
PT1187629E (pt) 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
HUP0202885A3 (en) 1999-09-24 2004-07-28 Smithkline Beecham Biolog Vaccines
TR200200777T2 (tr) 1999-09-24 2002-09-23 Smithkline Beecham Biologicals S.A. Polioksietilen alkil eteri veya esteriyle en az bir iyonik olmayan yüzey aktif maddeli adjuvant.
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
CN101721362B (zh) * 2002-02-14 2018-07-03 中外制药株式会社 包含抗体的溶液制剂
JP4393382B2 (ja) * 2002-08-14 2010-01-06 三菱化学株式会社 中枢性タウ蛋白質特異的抗体
JP4504098B2 (ja) * 2003-05-28 2010-07-14 武田薬品工業株式会社 抗体およびその用途
KR20130065723A (ko) * 2003-06-27 2013-06-19 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
ATE530165T1 (de) * 2003-11-14 2011-11-15 Baxter Int Alpha1-antitrypsin-zusammensetzungen und behandlungsverfahren unter verwendung dieser zusammensetzungen
US20060287263A1 (en) 2004-07-18 2006-12-21 Csl Limited Methods and compositions for inducing antigen-specific immune responses
EP1776105A2 (en) 2004-07-18 2007-04-25 Coley Pharmaceutical Group, Ltd Methods and compositions for inducing innate immune responses
US7887811B2 (en) * 2005-05-24 2011-02-15 Neovacs Method for preparing a stable immunogenic product comprising antigenic heterocomplexes of TNFα and a carrier protein
CN101594877A (zh) * 2005-11-02 2009-12-02 杜克大学 同时的化学疗法和免疫疗法
JP2010536341A (ja) * 2007-08-15 2010-12-02 アムニクス， インコーポレイテッド 生物学的に活性なポリペプチドの特性を改変するための組成物および方法
SG187410A1 (en) * 2007-12-28 2013-02-28 Baxter Int Recombinant vwf formulations

Also Published As

Publication number Publication date
MX2012007283A (es) 2012-07-30
EP3257525A2 (en) 2017-12-20
IL220308A0 (en) 2012-07-31
US20150087815A1 (en) 2015-03-26
WO2011077309A3 (en) 2011-10-06
CN102762224A (zh) 2012-10-31
SG10201408505SA (en) 2015-02-27
RU2012131162A (ru) 2014-01-27
AU2010334428B2 (en) 2015-05-21
SG181628A1 (en) 2012-07-30
US20190365886A1 (en) 2019-12-05
KR20120120185A (ko) 2012-11-01
US20130034573A1 (en) 2013-02-07
EP2515934B1 (en) 2017-05-17
JP6007105B2 (ja) 2016-10-12
JP2013515049A (ja) 2013-05-02
EP3257525A3 (en) 2018-02-28
EP2515934A2 (en) 2012-10-31
AU2010334428A1 (en) 2012-07-05
WO2011077309A2 (en) 2011-06-30
JP6146927B2 (ja) 2017-06-14
CN107412754A (zh) 2017-12-01
MX337070B (es) 2016-02-11
JP2015180667A (ja) 2015-10-15
NZ600978A (en) 2014-08-29
CA2785585A1 (en) 2011-06-30
RU2581020C2 (ru) 2016-04-10

Similar Documents

Publication Publication Date Title
NZ629256A (en) Vaccine compositions
MX2013001527A (es) Nuevas vacunas adyuvantes en base a adyuvantes de orientacion para anticuerpos directamente hacia celulas presentadoras de antigenos.
NZ604186A (en) Ige ch3 peptide vaccine
MX2012005782A (es) Procedimientos, composiciones y kits de liofilizacion.
MX2012005863A (es) Formulaciones de anticuerpos.
MY159156A (en) Antibody formulation
WO2008073448A3 (en) Pharmaceutical formulations and methods for making the same
WO2009022157A3 (en) Peptide with improved solubility
WO2011012637A3 (en) Subcutaneous anti-her2 antibody formulation
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
MY165831A (en) Methods of reducing virucidal activity in pcv-2 compositions and pcv-2 compositions with a improved immunogenicity
MX339068B (es) Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias.
EP3778917A3 (en) Multispecific antibodies, antibody analogs, compositions, and methods
AR077942A1 (es) Variantes de glucoamilasa
MX2012007676A (es) Nueva formulacion de anticuerpo.
WO2008112651A3 (en) Aminopyrimidines useful as inhibitors of protein kinases
WO2010040096A3 (en) Agonists of toll-like receptor 5 for the treatment of graft-versus-host disease
WO2008079973A9 (en) Egfr binding peptides and uses thereof
WO2009137778A3 (en) Methods and compositions for genetically engineering clostridia species
WO2010135527A3 (en) Elastin for soft tissue augmentation
PH12012500740A1 (en) Nutritional compositions including a high protein component and exogenous nucleotides
EP4296361A3 (en) Immunogenic composition
BRPI0820494A8 (pt) Métodos para preparar capecitabina e composto de carbonato de trialquila rico em beta-anômero usado no mesmo
WO2007014258A3 (en) Growth hormone secretagogues
WO2012119103A3 (en) Compositions and methods for mobilization of stem cells

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 08 DEC 2017 BY IN-LEGAL LIMITED

Effective date: 20160622

LAPS Patent lapsed